Ryvu Therapeutics S.A. Ryvu Therapeutics S.A.

Ryvu Therapeutics S.A.

RVU

Rank in Stocks #19699
Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to... Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise for development across hematological malignancies and solid tumors. This compound is presently in a Phase 1b clinical study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Among their other assets is SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, which is currently undergoing a Phase 2 clinical trial for acute myeloid leukemia. Furthermore, Ryvu's earlier research pipeline explores candidates in areas such as kinases, cancer metabolism, synthetic lethality, and immuno-oncology. The company, established in 2007, is based in Krakรณw, Poland.
Share Price
$4.51
Last synced: 2026-11-13
Market Cap
$98.24M
Change (1 day)
1.30%
Change (1 year)
-29.98%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Category

Healthcare
Operating Margin for Ryvu Therapeutics S.A. (RVU)
Operating Margin as of November 2026 TTM: -134.74%
According to Ryvu Therapeutics S.A.'s latest financial reports, its current operating margin (TTM) is -134.74%. At the end of 2025 the company had an operating margin of -196.22%.
Operating Margin history for Ryvu Therapeutics S.A. from 2010 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -134.74% -31.33%
2025 -196.22% 25.30%
2024 -156.60% -27.30%
2023 -215.42% 6.59%
2022 -202.10% -78.22%
2021 -927.76% 300.62%
2020 -231.58% 118.39%
2019 -106.04% 501.47%
2018 -17.63% -222.52%
2017 14.39% -671.03%
2016 -2.52% -149.90%
2015 5.05% -72.34%
2014 18.26% -212.86%
2013 -16.18% -75.67%
2012 -66.50% -8.33%
2011 -72.54% 116.47%
2010 -33.51% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -98.55%
US
33.87% -100.25%
US
-116.04% -99.14%
US
25.57% -100.19%
AU
31.23% -100.23%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Ryvu Therapeutics S.A.'s operating margin

What is Ryvu Therapeutics S.A.'s operating margin?

Ryvu Therapeutics S.A.'s operating margin is -134.74%, as of Nov 2026.

What was Ryvu Therapeutics S.A.'s operating margin in 2025?

In 2025, Ryvu Therapeutics S.A.'s operating margin was -196.22%, compared with -156.60% in 2024.

How has Ryvu Therapeutics S.A.'s operating margin changed since 2020?

From 2020 to 2025, Ryvu Therapeutics S.A.'s operating margin was highest in 2024 (-156.60%) and lowest in 2021 (-927.76%).

How does Ryvu Therapeutics S.A.'s operating margin compare with similar companies?

Ryvu Therapeutics S.A.'s operating margin (-134.74%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.